IMMUNOHISTOCHEMICAL EXPRESSION OF HEPATOCYTE GROWTH FACTOR/c-MET IN THE HEART AND AORTA OF DIABETIC RATS

被引:1
作者
Tekmen, I. [1 ]
Micili, S. Cilaker [1 ]
Arici, M. A. [1 ]
Guneli, M. E. [1 ]
Gumustekin, M. [1 ]
机构
[1] Dokuz Eylul Univ, Sch Med, Izmir, Turkey
关键词
Diabetes Mellitus; immunohistochemistry; cardiovascular system; Hepatocyte growth factor; c-Met; FACTOR-RECEPTOR; STEM-CELLS; HGF; CARDIOMYOPATHY; ACTIVATION; FAILURE; TISSUES; INJURY;
D O I
10.4183/aeb.2014.21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context. Diverse physiological or pathological events which are stimulated or contributed by HGF/c-Met pathway overlap by processes that play roles in etiopathogenesis of diabetes. Objective. In this study, it was aimed to analyse hepatocyte growth factor (HGF) and its receptor c-Met by immunohistochemistry in the heart and aorta tissues of diabetic and insulin-treated diabetic rats. Subjects and Methods. Accordingly, 21 rats were (equally) divided into three groups: Control (C), Diabetic (D), and Insulin-treated Diabetic (D + I). Rats were treated with Streptozotocin (STZ) (45 mg/kg, i.p.) to induce diabetes. Rats in the control group were given saline once a day for 8 weeks, while rats in the D + I group received 6 U/kg NPH insulin once daily for 8 weeks. The heart and aorta tissues were examined with immunohistochemistry, using antibodies against HGF and c-Met. Results. HGF and c-Met expressions were observed to be increased both in heart and aorta tissues in group D, whereas they decreased in group D+I. Conclusions. As a result, insulin treatment was determined to have a reducing effect on the increased expression of HGF and c-Met in diabetic heart and aorta. According to our results, increased HGF ve c-Met values observed in the myocardium and aorta in diabetes, are shown to increase in parallel to tissue damage and decrease by insulin treatment which is an effective therapy method.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 29 条
[1]   Diabetic cardiomyopathy [J].
Bell, DSH .
DIABETES CARE, 2003, 26 (10) :2949-2951
[2]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[3]   Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells [J].
Boccaccio, Carla ;
Comoglio, Paolo M. .
NATURE REVIEWS CANCER, 2006, 6 (08) :637-645
[4]   IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].
BOTTARO, DP ;
RUBIN, JS ;
FALETTO, DL ;
CHAN, AML ;
KMIECIK, TE ;
VANDEWOUDE, GF ;
AARONSON, SA .
SCIENCE, 1991, 251 (4995) :802-804
[5]   Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats [J].
Castoldi, Giovanna ;
di Gioia, Cira R. T. ;
Bombardi, Camila ;
Perego, Carla ;
Perego, Lucia ;
Mancini, Massimiliano ;
Leopizzi, Martina ;
Corradi, Barbara ;
Perlini, Stefano ;
Zerbini, Gianpaolo ;
Stella, Andrea .
CLINICAL SCIENCE, 2010, 118 (3-4) :211-220
[6]  
Dar KA, 2007, CELL BIOCHEM FUNCT, V25, P603
[7]   A study comparing the effects of rosiglitazone and/or insulin treatments on streptozotocin induced diabetic (type I diabetes) rat aorta and cavernous tissues [J].
Elcioglu, H. Kubra ;
Kabasakal, Levent ;
Ozkan, Naziye ;
Celikel, Cigdem ;
Ayanoglu-Dulger, Gul .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 660 (2-3) :476-484
[8]   Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats [J].
Guan, Sheng-jiang ;
Ma, Zhi-hong ;
Wu, Yan-ling ;
Zhang, Jian-ping ;
Liang, Feng ;
Weiss, J. Woodrow ;
Guo, Qian-yu ;
Wang, Jiang-yan ;
Ji, En-sheng ;
Chu, Li .
FOOD AND CHEMICAL TOXICOLOGY, 2012, 50 (06) :1874-1882
[9]   The Effect of Insulin Treatment on Rac1 Expression in Diabetic Kidney [J].
Gumustekin, Mukaddes ;
Micili, Serap Cilaker ;
Arici, Mualla Aylin ;
Karaman, Meral ;
Guneli, Mehmet Ensari ;
Tekmen, Isil .
RENAL FAILURE, 2013, 35 (03) :396-402
[10]   The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure [J].
Jin, HK ;
Wyss, JM ;
Yang, RH ;
Schwall, R .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (20) :2525-2533